Cortexyme Cortexyme has completed its merger with Novosteo, a biopharmaceutical company that develops drugs for rare skeletal diseases and bone cancer. Novosteo shareholders received 15.5% of the combined company, which will change its name to Quince Therapeutics in the coming months. Cortexyme also granted the transferred employees from Novosteo stock options of 3,74...